# US 2021/0171601 A1 · Leucine zipper-based compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171601 A1
- Document ID: US20210171601A1
- Status: Published application
- Kind: A1
- Application number: 17/176,533
- Filed: 2021-02-16
- Published: 2021-06-10
- Earliest claimed: 2018-08-16
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan-Kettering Cancer Center
- Inventors: Scott E. JAMES; Marcel R.M. VAN DEN BRINK; Lorenz JAHN
- Web page: https://patentgrep.com/patent/US20210171601A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/36: Immune checkpoint inhibitors
- A61K 40/4211: {CD19 or B4}
- A61K 40/4221: {CD20}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/54: Interleukins [IL]
- C07K 14/5403: {IL-3}
- C07K 14/5443: {IL-15}
- C07K 14/70507: {CD2}
- C07K 14/70514: {CD4}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2887: {against CD20}
- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- C12Y 304/22062: Caspase-9 (3.4.22.62)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 2239/13: Antibody-based
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/41: containing a Myc-tag
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

## Claims

### Claim 1

A system, comprising:
a) a membrane-bound polypeptide comprising: i) a transmembrane domain, ii) an intracellular domain, and iii) an extracellular domain that comprises a first dimerization domain and a blocking spacer, and
b) a soluble polypeptide comprising i) a second dimerization domain, and ii) an antigen binding domain that binds to an antigen,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain, and the blocking spacer prevents dimerization of the membrane-bound polypeptide with the soluble polypeptide when the membrane-bound polypeptide and the soluble polypeptide are not expressed from the same cell.

### Claim 2 (depends on 1)

The system of claim 1, wherein the blocking spacer has a length of no more than about 25 amino acids.

### Claim 3 (depends on 1)

The system of claim 1, wherein the blocking spacer has a length of between about 5 amino acids and about 25 amino acids.

### Claim 4 (depends on 1)

The system of claim 1, wherein the blocking spacer is a truncated CD28 spacer or an IgG1 hinge.

### Claim 5

A system, comprising:
a) a membrane-bound polypeptide comprising: i) a transmembrane domain, ii) an intracellular domain, and iii) an extracellular domain that comprises a first dimerization domain and a second dimerization domain that is capable of dimerizing with the first dimerization domain, and
b) a soluble polypeptide comprising i) a third dimerization domain that is capable of dimerizing with the first dimerization domain, and ii) an antigen binding domain that binds to an antigen,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain.

### Claim 6 (depends on 1)

The system of claim 1, wherein the antigen is selected from the group consisting of tumor antigens, pathogen antigens, immune checkpoint molecules, activating receptors, and biomarkers of a hematopoietic lineage cell.

### Claim 7 (depends on 1)

The system of claim 1, wherein the antigen is a tumor antigen.

### Claim 8 (depends on 7)

The system of claim 7, wherein the tumor antigen is selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, VpreB, CD30, CD33, CD38, CD40, CD44v6, CD70, CD79a, CD70b, CLL-1/CLEC12A, CD123, IL-3R complex, TIM-3, BCMA, TACI, SLAMF7, CD244, Epcam, E-cadherin, B7-H3, B7-H4, and combinations thereof.

### Claim 9 (depends on 1)

The system of claim 1, wherein the antigen is an activating receptor.

### Claim 10 (depends on 9)

The system of claim 9, wherein binding of the antigen binding domain to the activating receptor is capable of activating an antigen presenting cell (APC), and/or the activating receptor is selected from the group consisting of CD40, Toll Like Receptors (TLRs), FLT3, RANK, GM-CSF receptor, and combinations thereof.

### Claim 11 (depends on 10)

The system of claim 10, wherein the APC is a professional APC, a non-professional APC, or a cell of the myeloid lineage.

### Claim 12 (depends on 11)

The system of claim 11, wherein
a) the professional APC is selected from the group consisting of dendritic cells, macrophages, B cells, and combinations thereof; and/or
b) the cell of myeloid lineage is selected from the group consisting of dendritic cells, macrophages, monocytes and combinations thereof.

### Claim 13 (depends on 1)

The system of claim 1, wherein the antigen is an immune checkpoint molecule.

### Claim 14 (depends on 13)

The system of claim 13, wherein binding of the antigen binding domain to the immune checkpoint molecule is capable of blocking an immune checkpoint signal in an immunoresponsive cell, and/or the immune checkpoint molecule is selected from the group consisting of PD-L1, CD200, B7-H3, B7-H4, HVEM, Galectin9, PD-1, CTLA-4, CD200R, TIM-3, Lag-3, TIGIT, fragments thereof, and combinations thereof.

### Claim 15 (depends on 1)

The system of claim 1, wherein the antigen is a biomarker of a hematopoietic lineage cell.

### Claim 16 (depends on 15)

The system of claim 15, wherein the biomarker of a hematopoietic lineage cell is selected from the group consisting of CD3, CD16, CD33, c-Kit, CD161, CD19, CD20, VpreB, luteinizing hormone receptor (LHCGR), CD123, IL-3R complex, CLEC12A/CLL-1, fragments thereof, and combinations thereof.

### Claim 17 (depends on 15)

The system of claim 15, comprising at least four soluble polypeptides, wherein the antigen binding domain of each soluble polypeptide binds to a different biomarker of a hematopoietic lineage cell.

### Claim 18 (depends on 17)

The system of claim 17, comprising a first soluble polypeptide that binds to CD3, a second soluble polypeptide that binds to CD19, a third soluble polypeptide that binds to CD161 and a fourth soluble polypeptide that binds to c-Kit.

### Claim 19 (depends on 1)

The system of claim 1, further comprising:
c) a chimeric antigen receptor (CAR) comprising a second antigen binding domain, a transmembrane domain, and an intracellular activating domain.

### Claim 20 (depends on 19)

The system of claim 19, wherein the system further comprises d) an inhibitory receptor comprising a leucine zipper domain, wherein the inhibitory receptor binds to a third antigen.

### Claim 21 (depends on 20)

The system of claim 20, wherein the inhibitory receptor is a tyrosine phosphatase-based inhibitory receptor.

### Claim 22 (depends on 21)

The system of claim 21, wherein the tyrosine phosphatase is selected from the group consisting of PTPRJ, PTPRC, PTPN22, and PTPN6.

### Claim 23 (depends on 20)

The system of claim 20, wherein the inhibitory receptor constitutively inhibits and/or deactivates the CAR in the absence of the third antigen, and/or binding of the inhibitory receptor to the third antigen prevents the inhibition and/or deactivation of the CAR by the inhibitory receptor.

### Claim 24

A system, comprising:
a) a membrane-bound polypeptide comprising a transmembrane domain, an intracellular domain and an extracellular domain that comprises a first dimerization domain, and
b) a soluble polypeptide comprising a second dimerization domain that is capable of dimerizing with the first dimerization domain, and a cytokine or a chemokine,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain.

### Claim 25 (depends on 1)

The system of claim 1, wherein the extracellular domain of the membrane-bound polypeptide further comprises
a) a linker between the first dimerization domain and the second dimerization domain;
b) a spacer/hinge domain between the first dimerization domain and the transmembrane domain
c) a co-stimulatory ligand or a fragment thereof and/or
d) a dominant negative form of a molecule or a fragment thereof.

### Claim 26 (depends on 25)

The system of claim 25, wherein
a) the linker comprises the amino acid sequence set forth in SEQ ID NO: 3;
b) the spacer/hinge domain comprises i) an epitope recognized by an antibody, wherein binding of the antibody to the epitope mediates depletion of a cell comprising the membrane-bound polypeptide; and/or ii) a Thy1.1 molecule, a CD20 mimotope, or a truncated EGFR molecule (EGFRt);
c) the co-stimulatory ligand is selected from the group consisting of tumor necrosis factor (TNF) family members, immunoglobulin (Ig) superfamily members, and combinations thereof; and/or
d) the molecule is selected from the group consisting of inhibitors of immune checkpoint molecules, tumor necrosis factor receptor superfamily (TNFRSF) members, Transforming growth factor beta (TGFβ) receptors, and combinations thereof.

### Claim 27 (depends on 26)

The system of claim 26, wherein
a) the TNF family member is selected from the group consisting of 4-1BBL, OX40L, CD70, GITRL, CD40L, CD30L, and combinations thereof;
b) the Ig superfamily member is selected from the group consisting of CD80, CD86, ICOSLG, and combinations thereof;
c) the immune checkpoint molecule is selected from the group consisting of PD-1, CTLA-4, B7-H3, B7-H4, BTLA, TIM-3, LAG-3, TIGIT, LAIR1, CD200, CD200R, HVEM, 2B4, CD160, Galectin9, and combinations thereof; and/or
d) the TNFRSF member is selected from the group consisting of Fas, a Tumor necrosis factor receptor, OX40, CD40, CD27, CD30, 4-1BB, and combinations thereof.

### Claim 28 (depends on 1)

The system of claim 1, wherein the intracellular domain of the membrane-bound polypeptide comprises one or more immune activating molecules.

### Claim 29 (depends on 1)

The system of claim 1, wherein the intracellular domain of the membrane-bound polypeptide does not comprise one or more immune activating molecules.

### Claim 30 (depends on 1)

The system of claim 1, wherein the soluble polypeptide and the membrane-bound polypeptide are a) capable of forming a dimer when expressed from the same cell, and/or b) are not capable of forming a dimer when expressed from different cells due to the dimerization between the first dimerization domain and the second dimerization domain of the membrane-bound polypeptide.

### Claim 31 (depends on 1)

The system of claim 1, wherein the intracellular domain of the membrane-bound polypeptide comprises a CD3-ζ domain, a costimulatory domain, or a fragment or a combination thereof.

### Claim 32 (depends on 1)

The system of claim 1, further comprising a suicide molecule.

### Claim 33 (depends on 32)

The system of claim 32, wherein the suicide molecule is an inducible Caspase 9 polypeptide (iCasp9).

### Claim 34 (depends on 1)

The system of claim 1, wherein the membrane-bound polypeptide and/or the soluble polypeptide further comprises a tag or a mimotope recognized by an antibody, wherein binding of the antibody to the mimotope mediates depletion of a cell comprising the membrane-bound polypeptide.

### Claim 35 (depends on 34)

The system of claim 34, wherein
a) the tag comprises an epitope tag that is recognized by a first antibody or an affinity tag that binds to a substrate; and/or
b) the mimotope is CD20.

### Claim 36 (depends on 35)

The system of claim 35, wherein
a) the epitope tag is selected from the group consisting of a Myc-tag, a HA-tag, a Flag-tag, a V5-tag, a T7-tag, and combinations thereof; and/or
b) the affinity tag is selected from the group consisting of a His-tag, a Strep-tag, an E-tag, a streptavidin binding protein tag (SBP-tag), and combinations thereof.

### Claim 37 (depends on 1)

The system of claim 1, wherein the antigen binding domain comprises a single-chain variable fragment (scFv), a soluble ligand, a cytokine, a non-scFv-based antigen recognition motif, or a combination thereof.

### Claim 38 (depends on 1)

The system of claim 1, wherein the membrane-bound polypeptide is expressed from a first vector, and/or the soluble polypeptide is expressed from a second vector.

### Claim 39 (depends on 38)

The system of claim 38, wherein the first vector and/or the second vector is a viral vector or a transposon-based vector.

### Claim 40 (depends on 1)

The system of claim 1, wherein the leucine zippers are orthogonal zippers.

### Claim 41 (depends on 1)

A cell comprising the system of claim 1.

### Claim 42 (depends on 41)

The cell of claim 41, wherein the cell is an immunoresponsive cell, and/or a cell of the lymphoid lineage or a cell of the myeloid lineage.

### Claim 43 (depends on 42)

The cell of claim 42, wherein the cell of the lymphoid lineage is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a stem cell from which a lymphoid cell may be differentiated.

### Claim 44 (depends on 43)

The cell of claim 43, wherein the cell is a T cell.

### Claim 45 (depends on 44)

The cell of claim 44, wherein the T cell is selected from the group consisting of a cytotoxic T lymphocytes (CTL), a regulatory T cell, a Natural Killer T (NKT) cell, and combinations thereof.

### Claim 46 (depends on 41)

The cell of claim 41, wherein the cell is autologous or allogeneic.

### Claim 47 (depends on 41)

A pharmaceutical composition comprising the cell of claim 41 and one or more pharmaceutically acceptable excipients.

### Claim 48 (depends on 1)

A method for increasing an immune activity of an immunoresponsive cell; reducing tumor burden in a subject; treating and/or preventing a neoplasm in a subject; activating an antigen presenting cell (APC) in a subject; and/or conditioning a subject for bone marrow transplant, comprising introducing to the immunoresponsive cell the system of claim 1.

### Claim 49

A nucleic acid composition comprising
(a) a first polynucleotide encoding a membrane-bound polypeptide comprising: i) a transmembrane domain, ii) an intracellular domain, and iii) an extracellular domain that comprises a first dimerization domain and a blocking spacer, and
(b) a second polynucleotide encoding a soluble polypeptide comprising i) a second dimerization domain, and ii) an antigen binding domain that binds to an antigen,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain, and the blocking spacer prevents dimerization of the membrane-bound polypeptide with the soluble polypeptide when the membrane-bound polypeptide and the soluble polypeptide are not expressed from the same cell.

### Claim 50

A nucleic acid composition comprising
(a) a first polynucleotide encoding a membrane-bound polypeptide comprising: i) a transmembrane domain, ii) an intracellular domain, and iii) an extracellular domain that comprises a first dimerization domain and a second dimerization domain that is capable of dimerizing with the first dimerization domain, and
(b) a second polynucleotide encoding a soluble polypeptide comprising i) a third dimerization domain that is capable of dimerizing with the first dimerization domain, and ii) an antigen binding domain that binds to an antigen,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain.

### Claim 51

A nucleic acid composition comprising
(a) a first polynucleotide encoding a membrane-bound polypeptide comprising a transmembrane domain and an extracellular domain that comprises a first dimerization domain, and
(b) a second polynucleotide encoding a soluble polypeptide comprising a second dimerization domain that is capable of dimerizing with the first dimerization domain, and a cytokine or a chemokine,
wherein each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain.

### Claim 52 (depends on 49)

A combination of vectors comprising the nucleic acid composition of claim 49.
